Excitatory and inhibitory responses mediated by GABAA and GABAB receptors in guinea pig distal colon

1993 ◽  
Vol 230 (2) ◽  
pp. 187-193 ◽  
Author(s):  
Anil Minocha ◽  
James J. Galligan
2014 ◽  
Vol 731 ◽  
pp. 93-99 ◽  
Author(s):  
Michelangelo Auteri ◽  
Maria Grazia Zizzo ◽  
Mariangela Mastropaolo ◽  
Rosa Serio

1985 ◽  
Vol 84 (4) ◽  
pp. 883-895 ◽  
Author(s):  
A. Giotti ◽  
S. Luzzi ◽  
C.A. Maggi ◽  
S. Spagnesi ◽  
Lucilla Zilletti

Life Sciences ◽  
1991 ◽  
Vol 48 (15) ◽  
pp. PL69-PL72 ◽  
Author(s):  
Paolo Santicioli ◽  
Manuela Tramontana ◽  
Elena Del Bianco ◽  
Carlo Alberto Maggi ◽  
Pierangelo Geppetti

2003 ◽  
Vol 547 (2) ◽  
pp. 589-601 ◽  
Author(s):  
David R. Linden ◽  
Keith A. Sharkey ◽  
Gary M. Mawe
Keyword(s):  

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 709
Author(s):  
Bradley M. Roberts ◽  
Emanuel F. Lopes ◽  
Stephanie J. Cragg

Striatal dopamine (DA) release is critical for motivated actions and reinforcement learning, and is locally influenced at the level of DA axons by other striatal neurotransmitters. Here, we review a wealth of historical and more recently refined evidence indicating that DA output is inhibited by striatal γ-aminobutyric acid (GABA) acting via GABAA and GABAB receptors. We review evidence supporting the localisation of GABAA and GABAB receptors to DA axons, as well as the identity of the striatal sources of GABA that likely contribute to GABAergic modulation of DA release. We discuss emerging data outlining the mechanisms through which GABAA and GABAB receptors inhibit the amplitude as well as modulate the short-term plasticity of DA release. Furthermore, we highlight recent data showing that DA release is governed by plasma membrane GABA uptake transporters on striatal astrocytes, which determine ambient striatal GABA tone and, by extension, the tonic inhibition of DA release. Finally, we discuss how the regulation of striatal GABA-DA interactions represents an axis for dysfunction in psychomotor disorders associated with dysregulated DA signalling, including Parkinson’s disease, and could be a novel therapeutic target for drugs to modify striatal DA output.


2018 ◽  
Vol 39 (6) ◽  
pp. 1058-1065 ◽  
Author(s):  
Emanuel F. Lopes ◽  
Bradley M. Roberts ◽  
Ruth E. Siddorn ◽  
Michael A. Clements ◽  
Stephanie J. Cragg

Sign in / Sign up

Export Citation Format

Share Document